Results: Baseline VA intakes and intervention reach varied by geographic macro-region.

VA change after the first injection was driven largely by baseline characteristics such as age, baseline VA and lesion size.

Baseline VA and genotype of rs10490924 were both important predictors for visual response to bevacizumab at 6 months.

Visual acuity outcomes favored the E10030 1.5 mg combination therapy group regardless of baseline VA, lesion size, or central subfield thickness on optical coherence tomography.